SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
AZN Analysis & Videos »
AZN: Bull or Bear?
FDA Calendar Updates: POZN, AZN, SNY, CEPH, APPY, CYTR
AZN
|
|
|
-1.80%
in
4 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
FDA Calendar Updates at BioMedReports.com
AZN
|
|
|
-2.24%
in
5 days
(closed on 06/30/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
FDA, Clinical Trial Calendars: Cancer Drug Updates from ASCO
AZN
|
|
|
+7.89%
in
25 days
(closed on 06/25/09)
<> Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete respon...
|
FDA, Clinical Trial Calendar Updates: AZN, IMGN, MIPI, MELA
AZN
|
|
|
+9.36%
in
20 days
(closed on 05/31/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
Updated FDA, Clinical Trial Calendars: AZN, MYGN, NVS, PSDV
AZN
|
|
|
+10.58%
in
33 days
(closed on 05/11/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 113 entries through 4/8/09. The FDA Calendar includes the following information: company name, ticker, decision ...
|
FDA, Clinical Trial Calendar Updates: Weight Loss, Diabetes, and More
AZN
|
|
|
-3.60%
in
7 days
(closed on 04/08/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 110 entries through 4/1/09. The FDA Calendar includes the following information: company name, ticker, decision d...
|
Upcoming FDA Advisory Panel Meetings
AZN
|
|
|
-18.57%
in
23 days
(closed on 04/01/09)
A trio of diabetes drug candidates are affected by a tougher stance at the FDA for this class of drugs, which is focused on cardiovascular risks such as heart attack and stroke. Two of the drugs will be reviewed at early April FDA advisory panel meeting while a third will likely require additional clinical trials. http://www.biomedreports.com/fda-calendar.html <> In December the FDA issued a new guidance document that recommended more stringent clinical trials for diabetes drugs to better assess heart attack and stroke risks. In a change that was effective immediately,...
|
Updated Clinical Trial and FDA Decision Calendars
AZN
|
|
|
+3.16%
in
5 days
(closed on 03/09/09)
Posted by: Mike Havrilla in Untagged on Mar 04, 2009 <!-- Post Teaser Text --> <> Below are some recent updates to the BioMedReports.com -- FDA and Clinical Trial Calendars : <> 1.) Auxilium Pharma (AUXL): 3/2/09 BLA submission with priority review request for XIAFLEX (clostridial collagenase for injection), a novel, first-in-class, orphan-designated biologic for the treatment of Dupuytren's contracture. 5/2/09 is the date for FDA to accept the filing for review and decide on prior...
|
AstraZeneca Should Clear Hurdles
AZN
+1.96%
in
375 days
Management is determined to grow earnings largely through expanding its top-line and only secondarily through cost-cutting, share buybacks and productivity initiatives.
|
Turnaround time for drug stocks? 10 top picks
AZN
-27.03%
in
273 days
(closed on 03/04/09)
Filed under: Pfizer (PFE), Newsletters, Johnson and Johnson (JNJ), Abbott Laboratories (ABT), Bristol-Myers Squibb (BMY), Merck and Co (MRK), Lilly (Eli) (LLY), Stocks to Buy  "You can invest for all the right reasons and still get the wrong result," notes long-standing turnaround stock expert George Putnam, referring to the poor performance of the pharmaceutical sector in recent years.
<>Here, in his industry-leading The Turnaround Letter, he offers a fascinating review of 10 leading drug stocks which he now believes offer a combination of growth potential at "pretty cheap" valuations. Here is ...
|
Turnaround time for pharmaceuticals?
AZN
|
|
|
-1.01%
in
399 days
 "You can invest for all the right reasons and still get the wrong result," says George Putnam, referring to the poor performance of the pharmaceutical sector in recent years.
Here, in his industry-leading The Turnaround Letter, he offers a fascinating review of 10 leading drug stocks which he now believes offer a combination of growth potential at "pretty cheap" valuations. "In 2000 and 2001, when the Internet boom was becoming a bust, many smart investors turned away from technology stocks and put their money into drug stocks. How could you go wrong with the big pharmaceutical companies? <>"D...
|
AZN Earnings Beat Guidance and Consensus, Positive R&D Update
AZN
+14.28%
in
463 days
1/31 - "Revenues at $29,559 million (+7% CER) vs. consensus $29,279 million, operating profit $8,094 million vs. consensus $8,035 million, reported EPADR (earnings per ADR) $3.74 consensus $3.72. EPADR on guidance basis $4.20 vs. $3.98-$4.13 range. Core EPADR (ex. intangible. amortisation. and restructuring) $4.38, guidance for ’08 core EPADR $4.40-4.70, or 0-7% growth."
"Positive R&D Update — Company believes it is on target to bring on average two new medicines to market each year from 2010 onwards. Small molecule respiratory, inflammatory disease and cancer effort will be reduced."
"We...
|
People Bullish on AZN
People Bearish on AZN
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Be the first to start a discussion and earn 2 points.
More Resources
|
About AstraZeneca PLC
- Answers.com
